SCHEMBL565806

SCHEMBL565806

COC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O

nearest known ligand 0.39

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MPI P34949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759189 1.00 MPI (0.39) MPI
SCHEMBL5453964 1.00 MPI (0.39) MPI
SCHEMBL20280850 1.00 MPI (0.39) MPI
SCHEMBL1586372 1.00 MPI (0.39) MPI
SCHEMBL16344680 0.93 MPI (0.41) MPI
SCHEMBL11063688 0.93 MPI (0.41) MPI
SCHEMBL3441509 0.93 MPI (0.41) MPI
SCHEMBL22323284 0.93 MPI (0.41) MPI
SCHEMBL12289164 0.85 MPI (0.37) MPI
SCHEMBL7149026 0.82 MPI (0.36) MPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320175-A1 Acetoacetate Based Ketals ARXADA AG (CH) 2025-10-16 US claimed
EP-4605371-A1 POLYOL-DERIVED COMPOUNDS Arxada AG (CH) 2025-08-27 EP claimed
WO-2025074001-A2 ENZYMATIC REDUCTION OF ACETOACETATE ARXADA AG (CH) 2025-04-10 WO claimed
US-20250066408-A1 Polyol-Derived Compounds ARXADA AG (CH) 2025-02-27 US claimed
US-20250002446-A1 Acetoacetate Based Ketals ARXADA AG (CH) 2025-01-02 US claimed
US-20240336646-A1 Polyol-Derived Compounds ARXADA AG (CH) 2024-10-10 US claimed
CN-118591523-A Polyol-derived compounds 阿萨达股份公司 2024-09-03 CN claimed
EP-4412987-A1 ACETOACETATE BASED KETALS Arxada AG (CH) 2024-08-14 EP claimed
EP-4405324-A1 POLYOL-DERIVED COMPOUNDS Arxada AG (CH) 2024-07-31 EP claimed
WO-2024083889-A1 POLYOL-DERIVED COMPOUNDS ARXADA AG (CH) 2024-04-25 WO claimed
WO-2023094654-A1 ACETOACETATE BASED KETALS ARXADA AG (CH) 2023-06-01 WO claimed
WO-2023083570-A1 POLYOL-DERIVED COMPOUNDS ARXADA AG (CH) 2023-05-19 WO claimed
CN-100375755-C Longleaf Grateloupia acuminata polysaccharide extract and its prepn and use SHANGHAI TRADITIONAL CHINESE M (CN) 2008-03-19 CN claimed
CN-101077356-A Application for polysaccharide extraction of grateloupia filicina in preparing antitumor medicine and other medicines UNIV SHANGHAI OF T C M (CN) 2007-11-28 CN claimed
CN-1810842-A Longleaf Grateloupia acuminata polysaccharide extract and its prepn and use SHANGHAI TRADITIONAL CHINESE M (CN) 2006-08-02 CN claimed
EP-0130054-B1 NOVEL FRUCTOSYLTRANSFERASE, PROCESS FOR THE PREPARATION OF FRUCTOSYL DISACCHARIDES, AND A NOVEL HALOSUCROSE TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1990-03-07 EP claimed
US-4617269-A WITH TRANSFERASE ENZYMES DERIVED FROM BACILLUS TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1986-10-14 US claimed
JP-5244908-A None JP disclosed
US-4617269-A WITH TRANSFERASE ENZYMES DERIVED FROM BACILLUS TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1986-10-14 US disclosed
JP-H00892303-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336646-A1 Polyol-Derived Compounds PARG, SQLE, PARN MPI 343/4885
US-20250002446-A1 Acetoacetate Based Ketals KYAT1, KAT5, ALDOA MPI 2295/4885
US-20250320175-A1 Acetoacetate Based Ketals KYAT1, KAT5, ALDOA MPI 2295/4885
US-20250066408-A1 Polyol-Derived Compounds PARG, SQLE, PARN MPI 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.